Acute pancreatitis
Conditions
Interventions
Control group:After the patients fasting was lifted, a placebo was administered. The placebo was 5g/d on the 1st and 2nd days, 10g/d on the 3rd and 4th days, and 15g/d on the 5th to 28th days, twice a
Intervention group:After the patients fasting is lifted, inulin is administered. The dosage is 5g per day for the first and second days, 10g per day for the third and fourth days, and 15g per day for
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.AP patients who meet the 2012 Atlanta AP classification and diagnostic criteria; 2.Age 18-75 years old; 3.Within 72 hours of onset; 4.Willing to comply with study procedures, signed informed consent.
Exclusion criteria
Exclusion criteria: 1. >=2 organ failures (respiratory failure, circulatory failure, renal failure and intestinal failure) within 72 hours of onset; 2. Pancreatitis after endoscopic retrograde cholangiopancreatography; Biliary pancreatitis combined with acute purulent cholangitis; Presence of biliary infection before enrollment; Existing infectious necrosis of the pancreas before enrollment; Non-pancreatic infection or sepsis caused by a second disease before enrollment; 3. Metastatic malignant tumors, autoimmune diseases (such as systemic lupus erythematosus, autoimmune pancreatitis, giant cell arteritis, rheumatoid arthritis), chronic infectious diseases (including human immunodeficiency virus or tuberculosis), chronic pancreatitis, pancreatic cancer, hypothyroidism, nephrotic syndrome, Cushing's syndrome; 4. History of severe cardiovascular and cerebrovascular diseases and organ dysfunction, such as malignant tumors, heart failure, coronary heart disease, chronic obstructive pulmonary disease, liver and kidney failure; 5. Pregnant and lactating women; 6. Severe gastrointestinal diseases: combined with gastrointestinal fistula and unable to achieve remote feeding; digestive tract obstruction; Abdominal compartment syndrome; Upper gastrointestinal bleeding that has not stopped or shows signs of rebleeding; gastric juice extraction volume exceeds 500ml/6h, etc.; 7. Patients who are allergic to inulin; 8. Uncontrolled life-threatening hypoxemia, hypercapnia, or acidosis; 9. The patient is in uncontrolled shock and does not meet hemodynamic and tissue irrigation goals; 10. Participation in a study involving other foods or drugs or participation in other research studies during this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The changes in the abundance of various intestinal flora;The changes of short-chain fatty acids before and after treatment; | — |
Countries
China
Contacts
Public ContactCong He
The First Affiliated Hospital of Nanchang University
Outcome results
None listed